Issue 1/2011
Content (14 Articles)
B-cell–Targeted Therapy for the Fibrotic Complications of Systemic Sclerosis
Robert Woodrick, John Varga
Biomarkers in the Management of Scleroderma: An Update
Giuseppina Abignano, Maya Buch, Paul Emery, Francesco Del Galdo
Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials
Naoki Iwamoto, Jörg H. W. Distler, Oliver Distler
A Unifying Hypothesis for Scleroderma: Identifying a Target Cell for Scleroderma
William M. Mahoney Jr, Jo Nadine Fleming, Stephen M. Schwartz
The Scleroderma Kidney: Progress in Risk Factors, Therapy, and Prevention
Guillaume Bussone, Alice Bérezné, Vincent Pestre, Loïc Guillevin, Luc Mouthon
Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations
Jessica Gordon, Robert Spiera
Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand?
Medha Barbhaiya, Doruk Erkan
Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I
Bas de Laat, Philip G. de Groot
New Insights into the Biology and Pathobiology of Beta2-Glycoprotein I
Bill Giannakopoulos, Peyman Mirarabshahi, Steven A. Krilis